San Diego-based Optimer Pharmaceuticals, a biopharmaceutical company focused on antibiotics, said Thursday that it has raised $32.9M in a registered direct offering from institutional investors. Those investors were not disclosed. The firm said it will sell 2,794,700 newly issued shares of its common stock at a purchase price of $10.00 per share. Optimer has two lead products, a antibiotic in phase 3 trials for Clostridium difficile infection, and an antibiotic for treating 'travelers' diarrhea'.
Top NewsThursday, March 5, 2009
Optimer Pharmaceuticals Raises $32.9M In PIPE